Related references
Note: Only part of the references are listed.Mechanisms of and obstacles to iron cardiomyopathy in thalassemia
Ching-Tien Peng et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Effects of chelation therapy on cardiac function improvement in thalassemia patients: Literature review and the Taiwanese experience
Ching-Tien Peng et al.
HEMOGLOBIN (2008)
Deferiprone or deferoxamine vs Combination therapyin patients with β-thalassemia major:: A case study in Taiwan
CT Peng et al.
HEMOGLOBIN (2006)
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major
Kang-Hsi Wu et al.
HEMOGLOBIN (2006)
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients
Yu-Chih Huang et al.
HEMOGLOBIN (2006)
Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations
GJ Kontoghiorghes et al.
CURRENT MEDICINAL CHEMISTRY (2005)
Tricuspid regurgitation in patients with β-thalassemia major
KH Wu et al.
ANNALS OF HEMATOLOGY (2004)
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major
KH Wu et al.
ANNALS OF HEMATOLOGY (2004)
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance
LJ Anderson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan
CT Peng et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Share Paper
